AstraZeneca has secured approval for its drug Imfinzi to treat an additional type of bladder cancer, expanding its therapeutic indications.

The CEO of AstraZeneca has warned that Japan risks falling behind in pharmaceutical innovation and access without significant reforms to its drug pricing policies.

AstraZeneca has secured approval from U.S. regulators for its new hypertension drug, expanding its pharmaceutical portfolio.

AstraZeneca's potential blockbuster blood pressure medication has received approval for use in the United States, offering a new treatment option for patients.

AstraZeneca has signed a cooperation agreement with the Institute of Applied Biosciences (INEB/EKETA) and Papageorgiou Hospital to leverage health data and enhance clinical research.

CDT Equity has advanced AstraZeneca PLC (AZN)’s compound AZD5904 into the Patent Cooperation Treaty (PCT) patent protection stage.

A series of financial articles provides analysis on whether various company stocks, including major players like Apple, Tesla, and Nvidia, represent good investment opportunities. These reports offer insights into potential buys in the current market.

An FDA panel has rejected the risk-benefit profile of an AstraZeneca cancer drug, raising questions about its approval.

Astrazeneca reported first-quarter results that surpassed expectations, primarily due to robust sales of its cancer medications.

Citi analysts have concluded that the ongoing supply review concerning Daiichi is unlikely to have a significant impact on AstraZeneca's financial performance or operations.

Albanian Prime Minister Edi Rama is scheduled to visit Greece to participate in the Delphi Economic Forum, with a meeting with Prime Minister Mitsotakis also on the agenda.

Pharmaceutical giant AstraZeneca is reportedly accelerating its efforts in the field of precision medicine.

The Serbian Health Insurance Fund (RFZO) and AstraZeneca have signed an agreement in Belgrade to include innovative oncology drugs on the RFZO list for cancer patients.

AstraZeneca announced positive results from a late-stage clinical trial for its Imfinzi regimen, demonstrating a win in the treatment of liver cancer.

AstraZeneca's drug for chronic lung disease has met its primary goals in late-stage trials, demonstrating its ability to reduce flare-ups, leading to a rise in the company's shares.

AstraZeneca's stock saw a boost after its new lung drug successfully met its objectives in late-stage clinical trials.

China has given its approval for an innovative breast cancer therapy developed jointly by pharmaceutical companies Daiichi Sankyo and AstraZeneca, expanding treatment options for patients.

AstraZeneca said it would establish drug manufacturing facilities in Guangzhou and Shanghai as well as a separate innovation centre in Shanghai, joining a group of foreign players building new plants…

AstraZeneca’s Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer  WSJ

Abivax stock saw its gains reduced after the company denied speculation regarding a potential deal or collaboration with AstraZeneca.

UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds Business live – latest updates The pipeline of drugs to fight superbugs remains “worryingly thin”…

Currently, many complex conditions can also be treated through minimally invasive procedures, which have become more accessible due to technological advancements.

AstraZeneca boss Pascal Soriot received £17.7 million in pay and bonuses for 2025, with his total compensation increasing by 6.4% due to significant bonuses and share awards.

A fact-checking report clarifies that claims linking the AstraZeneca vaccine to a 'path to death' are false, addressing misinformation surrounding the vaccine.

AstraZeneca announced that the FDA has delayed its review of the breast cancer therapy camizestrant, requesting more data for the drug.

Scientists in the UK are reportedly working on an Ebola vaccine that is based on the AstraZeneca COVID-19 jab.

AstraZeneca has announced a collaboration with Roche Diagnostics Asia Pacific to accelerate the development of a sustainable ecosystem. This partnership aims to foster environmental responsibility and innovation within the industry.

AstraZeneca, the Institute of Applied Biosciences (INEB/EKETA), and Papageorgiou General Hospital have formed a strategic partnership to boost clinical research in Greece, initially focusing on health data utilization for microangiopathic anemias.

Pharmaceutical giant AstraZeneca PLC announced robust financial results and raised its guidance, leading to a positive market reaction for its stock.

AstraZeneca's experimental breast-cancer drug candidate did not receive a favorable vote from an FDA panel, impacting its path to potential approval.

AstraZeneca actively participated in the Delphi Economic Forum XI, contributing to public discourse on the future of health and the role of innovative pharmaceutical industry in sustainability.

The FTSE 100 index closed lower, primarily impacted by the struggles and declining share prices of major pharmaceutical companies GSK and AstraZeneca.

AstraZeneca reported first-quarter 2026 earnings that surpassed expectations, largely attributed to strong sales of its cancer drugs. The pharmaceutical giant continues to see growth in its oncology portfolio.

Pharmaceutical companies Amgen and AstraZeneca have begun real-time drug trials, coinciding with the FDA's use of artificial intelligence to speed up drug development.

AstraZeneca PLC announced positive findings from a prespecified interim analysis of its I CAN Phase III clinical trial, indicating promising results for the studied treatment.

AstraZeneca has announced another successful late-stage clinical trial for its chronic obstructive pulmonary disease (COPD) therapy.

AstraZeneca reports that over 90% of its current research is based on precision medicine, reflecting a strategic shift in its drug development. The company's global plans include launching 20 new medications before the end of the decade.

Deutsche Bank has reiterated its 'Sell' rating on pharmaceutical giant AstraZeneca (AZN) stock. This financial assessment reflects the bank's current outlook on the company's market performance and future prospects.

AstraZeneca's drug for chronic lung disease has met its primary goals in late-stage trials, demonstrating its ability to reduce flare-ups and leading to a rise in the company's shares, as reported by the Wall Street Journal.

AstraZeneca's experimental drug for chronic obstructive pulmonary disease (COPD) has shown successful outcomes in two Phase 3 clinical trials, leading to a 4% jump in the company's stock.

The Greek Rare Patients Association (ESAE) and AstraZeneca Greece have announced a collaboration aimed at widely disseminating and actively utilizing the Greek Rare Diseases Map (rdgmap.gr).

Guggenheim has increased its price target for pharmaceutical giant AstraZeneca PLC (AZN) from 15,500 GBp to 16,000 GBp, indicating a more optimistic outlook for the company's stock.

Eli Lilly is reportedly considering re-entering the bidding process for Abivax, contingent on whether AstraZeneca fails to meet its acquisition deadline.

Morgan Stanley analysts project double-digit earnings per share (EPS) growth for AstraZeneca PLC (AZN), indicating a positive financial outlook for the pharmaceutical company.

Vor deutschen Gerichten sind Klagen gegen Impfstoffhersteller bisher oft gescheitert. Nun hat eine Zahnärztin aus Mainz vor dem Bundesgerichtshof einen Teilerfolg gegen AstraZeneca errungen.

Xencor's stock has declined following a royalty dispute with AstraZeneca, which led the company to cut its financial guidance.

Increase of 6.4% comes as drugmaker reports strong profit growth, despite cancelling UK investment projects Business live – latest updates Pascal Soriot, the chief executive of Britain’s largest pharmaceutical company, received a 6.4% pay rise last year, taking his total remuneration to £17.7m. The AstraZeneca boss is in line for a further increase this year, potentially making him the UK’s highest-paid chief executive once again. Continue reading...

Hedge funds are identifying Iovance Biotherapeutics Inc. (IOVA) and AstraZeneca PLC (AZN) as leading immunotherapy stocks to buy.

The FDA has extended its review period for an AstraZeneca breast cancer drug after an oncology advisory panel voted against recommending it.

AstraZeneca has received approval for its drug Datroway to be used as a first-line treatment for breast cancer, marking a significant development in oncology.

AstraZeneca has announced that its hypertension drug, Baxfendy, has received approval from the U.S. Food and Drug Administration (FDA). This approval marks a significant step for the treatment of hypertension.

AstraZeneca announced that its Imfinzi combination therapy demonstrated improved survival rates in a study for bladder cancer patients.

AstraZeneca PLC's stock experienced a decline after an FDA panel voted against the approval of its new cancer drug.

Pharmaceutical company AstraZeneca has partnered with the fifth edition of the CIM Forum – Festival of Creative Industries and Media, scheduled to take place from May 28 to 31, 2026, in Kotor, Montenegro.

An FDA advisory committee has voted against endorsing AstraZeneca's new breast cancer drug, camizestrant, leading to a decline in the company's stock. This decision marks a significant setback for the pharmaceutical giant's new treatment.

AstraZeneca has resumed £300 million in UK projects, particularly in Cambridge, following an agreement with the UK government to increase drug spending as part of a trade deal with the US.

Prime Minister Starmer announced that pharmaceutical giant AstraZeneca plans to invest $405 million in its operations within Britain.

A contract for 10 innovative oncology drugs was signed in April between Serbia's RFZO and AstraZeneca, but the exact start date for their implementation for patients remains unknown.

AstraZeneca PLC is presented as one of the best firms offering a combination of low risk and high growth potential in the market.

AstraZeneca's total investment in Poland has surpassed 5 billion Polish Zloty, with 1.27 billion PLN invested in 2025 alone, marking the highest annual expenditure in the company's history in the country since 2020.

Pharmaceutical giant AstraZeneca is reportedly facing significant business challenges in China while preparing for key drug launches. Despite these headwinds, two banks are projecting a 20% upside for the company's stock.

Guggenheim has increased its price target for AstraZeneca PLC (AZN) shares from 16,000 GBp to 16,500 GBp.

Guggenheim has increased its price target for AstraZeneca's stock in anticipation of the company's upcoming first-quarter earnings report.

AstraZeneca's drug for chronic lung disease has met its primary goals in late-stage trials, demonstrating its ability to reduce flare-ups and leading to a rise in the company's shares.

Several stocks, including AstraZeneca, Unity Software, and Coinbase, are experiencing significant movements in premarket trading.

AstraZeneca has announced that its drug Imfinzi has received approval in the European Union for the treatment of early gastric and gastroesophageal cancers.

AstraZeneca’s Imfinzi Gets Expanded EU Label With Approval for Gastric Cancer  WSJ

Σε συνάντησή της με εκπροσώπους του Τύπου, η Πρόεδρος και Διευθύνουσα Σύμβουλος της AstraZeneca Ελλάδας και Κύπρου, Έλενα Χουλιάρα, αναφέρθηκε συνολικά στις δραστηριότητες και τους στόχους της…

Chief executive and chairman of ICI in the 1990s who oversaw the creation of the pharmaceutical company Zeneca Ronnie Hampel was a businessman’s businessman, a major force in the reshaping of ICI, Britain’s largest manufacturing company, in the 1990s and in the birth of the pharmaceutical company Zeneca (now part of AstraZeneca), as well as a powerful influence on other company boards. He was exceptionally well-connected. His place at the heart of the UK business establishment as chairman of...

She receives a Covid vaccination and suffers a sudden hearing loss. Now the woman has brought the legal dispute with the vaccine manufacturer AstraZeneca before the Federal Supreme Court - and achieved partial success.

Agadir – Morocco celebrated International Rare Disease Day with the launch of a new Precision Medicine Hub at the Mohammed VI International University Hospital Complex on Friday in Rabat, a joint project by Fondation Mohammed VI des Sciences et de la Santé (FM6SS) and AstraZeneca.  The Hub aims to improve the diagnosis, treatment, and care […] The post Morocco Establishes National Hub to Advance Rare Disease Treatment appeared first on Morocco World News.

Tempo.co English published a fact-check article debunking the false claim that the name 'AstraZeneca' translates to 'path to death'.